Adverse drug events reactions in patients exposed to cancer chemotherapy, excluding neutropenic fever
| ATC* | Drug | Age† | Adverse drug event | Naranjo score‡ | Avoidable? | Licensing state |
|---|---|---|---|---|---|---|
| L | Methotrexate | Adolescent | Pancreatitis | 4 | No | Off-label |
| L | Vincristine | Adolescent | Constipation | 7 | No | Licensed |
| L | Vincristine | Child | Ataxia and diarrhoea | 9 | No | Licensed |
| L | Vincristine | Child | Ataxia and diarrhoea | 10 | No | Licensed |
| L | Asparagines | 7 | No | Licensed | ||
| L | Doxorubicin | 7 | No | Off-label | ||
| L | Vincristine | Adolescent | Retinal haemorrhage | 7 | No | Licensed |
| L | Carboplatin | 9 | No | Unlicensed | ||
| L | Etoposide | Child | Vomiting | 9 | No | Unlicensed |
| L | Cisplatin | 9 | No | Unlicensed | ||
| L | Dexrazoxaan | 9 | No | Off-label | ||
| L | Doxorubicin | Child | Anaemia | 9 | No | Unlicensed |
| L | Cytarabine | Trombopaenia, petechiea | 9 | No | Off-label | |
| L | Mitoxantrone | Adolescent | 9 | No | Unlicensed | |
| L | Cytarabine | Trombopaenia, petechiea | 10 | No | Off-label | |
| L | Mitoxantrone | Adolescent | 10 | No | Unlicensed | |
| L | Methotrexaat | 10 | No | Off-label | ||
| L | Mercaptopurine | 10 | No | Off-label | ||
| L | Vincristine | Child | Leucopaenia | 10 | No | Off-label |
| L | Vincristine | Baby/toddler | Constipation | 6 | No | Off-label |
*Anatomical Therapeutical Chemical (ATC) classification system of the WHO. A, alimentary tract and metabolism; C, cardiovascular system; J, anti-infectives for systemic use; L, antineoplastic and immunomodulating agents; N, nervous system.15
†Patient age by means of EMeA criteria: preterm, newborn (0–1 month), baby/toddler (1 month–2 years), child (2–11 years), adolescent (12–18 years).
‡Probability measured by Naranjo score: ≤0 Adverse Drug Reactions (ADR) doubtful, 1–4 ADR possible, 5–8 ADR likely, ≥9 ADR certain.11
EMeA, European Medicines (Evaluation) Agency.